Metraipolis › archive › dc_ed986374cec2
Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL) — Europe PMC PMID:42127092
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42127092
- DOI
- 10.1371/journal.pone.0342702
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T06:59:43.637Z
- SHA-256 of the archived text
4187d3e34b59a9347fc8517c20fe127c0cfd5b6ed8191823cec40b56cc9f8f7e- Stable URL of this page
https://metraipolis.com/documento/dc_ed986374cec2
How to cite
Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL) — Europe PMC PMID:42127092 — Europe PMC (en), https://europepmc.org/article/MED/42127092 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ed986374cec2 (Metraipolis archive dc_ed986374cec2, sha256 4187d3e34b59a9347fc8517c20fe127c0cfd5b6ed8191823cec40b56cc9f8f7e)
BibTeX
@misc{dced986374cec2,
title = {Feasibility of the Xemio app for breast cancer survivors in a clinical setting: Adherence, acceptance, and side effect monitoring (CTCAE vs. QoL) — Europe PMC PMID:42127092},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42127092},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ed986374cec2; sha256 4187d3e34b59a9347fc8517c20fe127c0cfd5b6ed8191823cec40b56cc9f8f7e},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42127092. Agents can read the archived copy with the MCP tool read_document.